PROK
NASDAQ · Biotechnology
Prokidney Corp
$1.80
+0.03 (+1.69%)
Open$1.80
Previous Close$1.77
Day High$1.87
Day Low$1.76
52W High$7.13
52W Low$0.54
Volume—
Avg Volume740.8K
Market Cap552.77M
P/E Ratio—
EPS$-0.53
SectorBiotechnology
Analyst Ratings
Buy
15 analysts
Price Target
+1,001.1% upside
Current
$1.80
$1.80
Target
$19.82
$19.82
$13.43
$19.82 avg
$25.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.08M | 45.98M | 42.93M |
| Net Income | -159,930,405 | 9.61M | 10.78M |
| Profit Margin | -7,725.2% | 20.9% | 25.1% |
| EBITDA | -367,312,008 | 17.18M | 13.92M |
| Free Cash Flow | — | 13.69M | 9.06M |
| Rev Growth | — | +20.4% | +3.7% |
| Debt/Equity | 0.00 | 0.62 | 0.57 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $243.73 | +3.76% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $356.32 | +1.39% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $124.43 | -0.58% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $484.49 | +1.96% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $625.11 | +0.27% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $291.90 | -0.73% | 64.3 | 37.13B |